Results 41 to 50 of about 8,420 (208)

Development of Novel Olmesartan Medoxomil Loaded Leciplex for Enhanced Oral Bioavailability: Formulation, Histopathological Analysis, and In Vivo Pharmacokinetic Studies

open access: yesJournal of Pharmaceutical Innovation
Olmesartan medoxomil (OLM), a widely prescribed antihypertensive agent, suffers from poor solubility and first pass metabolism, which lowers its bioavailability.
Hussein M. Eid   +5 more
semanticscholar   +1 more source

Hypertension: Focus on Olmesartan Medoxomil

open access: yes, 2009
Hypertension is the leading cause of stroke, heart failure, and ischemic heart disease. One of the key regulators of blood pressure is the renin-angiotensin aldosterone system (RAAS).
Allison M. Bell, Diane Nykamp
core   +1 more source

Olmesartan Medoxomil Nanomicelle Using Soluplus for Dissolution Enhancement :Preparation, In-vitro and Ex-vivo Evaluation

open access: yesIraqi Journal of Pharmaceutical Sciences
The antihypertensive medication olmesartan medoxomil (OLM) is pharmacologically selective  angiotensin-II receptor antagonist. Pharmaceutically speaking, OLM is a class II medication (low solubility, high permeability) that is practically insoluble.Due ...
N. Rajab, Halah Talal Sulaiman
semanticscholar   +1 more source

Preparation and Characterization of Olmesartan Medoxomil-Loaded Polymeric Mixed Micelle Nanocarrier

open access: yesIraqi Journal of Pharmaceutical Sciences
Olmesartan medoxomil (OLM) is a selective angiotensin II antagonist that effectively lowers blood pressure. It has a poor rate of absorption when taken orally, a maximum bioavailability of about 26%, and limited solubility in water.
H. T. Sulaiman, N. Rajab
semanticscholar   +1 more source

Clinical efficacy of olmesartan medoxomil.

open access: yes, 2003
Olmesartan medoxomil is a new angiotensin-II receptor antagonist for the treatment of hypertension. Olmesartan medoxomil is a pro-drug that is de-esterified to the active metabolite, olmesartan. Olmesartan has a dual method of elimination, with about 60%
Brunner HR, Laeis P
core   +1 more source

ELASTIC VESICLES FOR ENHANCING THE TRANSDERMAL DELIVERY OF OLMESARTAN MEDOXOMIL [PDF]

open access: yesBulletin of Pharmaceutical Sciences. Assiut University
Hypertension seems to be a disorder that needs consideration for developing a transdermal drug delivery system (TDDS) because it requires long and continuing therapy. Olmesartan Medoxomil is an antihypertensive medication which has substantial first pass
reem Al-Uobody   +2 more
doaj   +1 more source

Oxadiazolone‐Triazole Derivatives as a New Scaffold for Modulation of Angiotensin II‐Induced Vascular Contraction

open access: yesChemMedChem, Volume 21, Issue 17, 14 September 2026.
A novel series of candidate AT1 receptor antagonists based on oxadiazolone‐triazole scaffolds was designed and synthesized. Most compounds reduced angiotensin II‐induced vascular contraction in an initial biological screening, with compound 7f emerging as the most active derivative.
Larissa F. L. Ferreira   +5 more
wiley   +1 more source

Metal‐Catalyzed Transformations of Carbon Dioxide Toward the Production of Commodity Chemicals

open access: yesAdvanced Synthesis &Catalysis, Volume 368, Issue 17, 1 September 2026.
This perspective highlights how transition‐metal catalysis can enable the synthesis of economically attractive CO2‐derived commodity chemicals. By transforming waste CO2 into acrylic acid, cyclic carbonates, and other valuable products, these strategies provide a practical route for simultaneous CO2 sequestration and valorization, helping to align ...
Chaodi Dai   +2 more
wiley   +1 more source

A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?

open access: yesКардиоваскулярная терапия и профилактика, 2011
Angiotensin II receptor blockers (ARBs) have been available in the United Statessince 1995. These agents have demonstrated antihypertensive efficacy at least similar to that of agents from other antihypertensive classes.
M. Greathouse
doaj   +1 more source

A quality by design approach for the optimization of olmesartan medoxomil-orodispersible lyophilisates: In vitro/in vivo evaluation

open access: yesJournal of Applied Pharmaceutical Sciences, 2022
The current study aims to develop orodispersible lyophilisates (ODLs), containing olmesartan medoxomil (OLM), by applying a quality by design approach to ensure product robustness.
S. H. Noshi   +2 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy